A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Conditions:  Epstein-Barr Virus (EBV)-Associated Diseases;  EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD);  EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD);  EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous Syste m (CNS PTLD);  EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD);  Solid Organ Transplant Complications;  Lymphoproliferative Disorders;  Allogeneic Hematopoietic Cell Transplant;  Stem Cell Transplant Complications;  EBV+ Sarcomas;  Leiomyosarcoma;  Chronic Ac tive Epstein-Barr Virus (CAEBV);  Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH);  Lymphohistiocytosis, Hemophagocytic Intervention:  Biological: Tabelecleucel Sponsor:  Atara Biotherapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Leiomyosarcoma | Primary Immunodeficiency Disease | Research | Sarcomas | Study | Transplants